Journal-based CME Course: Progression of Presumed Pentosan Polysulfate Sodium Maculopathy After Drug Cessation

Activity ID

14594

Expires

December 18, 2028

Format Type

Journal-based

CME Credit

Fee

$30

CME Provider: JAMA Ophthalmology

Description of CME Course

This case report discusses presumed progression of maculopathy secondary to pentosan polysulfate sodium prescribed for daily use over a period of 4 years in a patient with a history of interstitial cystitis.

Disclaimers

1. This activity is accredited by the American Medical Association.
2. This activity is free to AMA members.

ABMS Member Board Approvals by Type

ABMS Lifelong Learning CME Activity

Allergy and Immunology

Anesthesiology

Colon and Rectal Surgery

Family Medicine

Medical Genetics and Genomics

Nuclear Medicine

Ophthalmology

Pathology

Physical Medicine and Rehabilitation

Plastic Surgery

Preventive Medicine

Psychiatry and Neurology

Radiology

Thoracic Surgery

Urology

More Information

Commercial Support?

NOTE: If a Member Board has not deemed this activity for MOC approval as an accredited CME activity, this activity may count toward an ABMS Member Board’s general CME requirement. Please refer directly to your Member Board’s MOC Part II Lifelong Learning and Self-Assessment Program Requirements.

General Information on CME Activity

Educational Objectives

To identify the key insights or developments described in this article

Keywords

Macular Diseases, Ophthalmic Images, Ophthalmology, Retinal Disorders, Anticoagulation

Competencies

Medical Knowledge

CME Credit Type

AMA PRA Category 1 Credit

DOI

10.1001/jamaophthalmol.2025.3642